PomDoctor Files For Nasdaq IPO That May Be Overvalued
1. PomDoc plans a Nasdaq listing to raise $30 million. 2. Company faces significant financial challenges with high liabilities. 3. Market capitalization targets appear aggressive compared to profitable competitors. 4. Focus on chronic disease management may provide a niche market advantage. 5. IPO success is uncertain due to shaky financial position and auditor concerns.